China Shineway Pharmaceutical Group Limited
CSWYFOTCHealthcare● Active
$1.08
+$0.08(+7.57%)
Market Cap$815832000
P/E Ratio—
52W High$1.08
52W Low$0.9253
China Shineway Pharmaceutical Group Limited (CSWYF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSWYF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $1.27B | $1.15B | $0.97B | $0.74B | $0.55B |
| Depreciation & Amort. | $0.07B | $0.07B | $0.06B | $0.06B | $0.06B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | $0.50B | $0.22B | ($0.17B) | $0.30B | $0.04B |
| Net Cash from Operations | $1.17B | $0.96B | $0.93B | $1.11B | $0.70B |
| Investing Activities | |||||
| Capital Expenditure | ($0.20B) | ($0.14B) | ($0.14B) | ($0.13B) | ($0.09B) |
| Purchases of Investments | ($0.80B) | ($0.84B) | ($0.52B) | ($0.31B) | ($0.36B) |
| Sales of Investments | $0.95B | $0.53B | $0.53B | $0.31B | $0.37B |
| Net Cash from Investing | $0.22B | ($0.27B) | ($0.05B) | ($0.05B) | $0.40B |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | ($0.36B) | ($0.41B) | ($0.32B) | ($0.24B) | ($0.45B) |
| Debt Issued / Repaid | ($0.00B) | $0.03B | $0.30B | ($0.01B) | ($0.37B) |
| Net Cash from Financing | ($0.38B) | ($0.39B) | ($0.03B) | ($0.25B) | ($0.81B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.97B | $0.82B | $0.85B | $1.09B | $0.67B |
| FCF Margin %(computed) | 31.07% | 21.78% | 2.66% | 27.08% | 21.21% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CNY · B
Explore more China Shineway Pharmaceutical Group Limited data
About China Shineway Pharmaceutical Group Limited (CSWYF) Cash Flow Statement
China Shineway Pharmaceutical Group Limited generated operating cash flow of $1.17B and free cash flow of $0.97B for 2025 — a FCF margin of 31.07%. Capital expenditure was ($0.20B).
Frequently asked questions
CSWYF · 4 questionsChina Shineway Pharmaceutical Group Limited generated free cash flow of $0.97B for 2025, up 18.4% year-over-year.
CSWYF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10